Litigation Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Docket		Date Filed	2015-08-24
Court	District Court, E.D. Texas	Date Terminated	2017-10-16
Cause	35:271 Patent Infringement	Assigned To	William C. Bryson
Jury Demand	Both	Referred To
Patents	8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,248,191
Link to Docket	External link to docket

Details for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. (E.D. Tex. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-24	1	Complaint	U.S. Patent No. 8,629,111, # 3 Exhibit 2 - U.S. Patent No. 8,633,162, # 4 Exhibit 3 - U.S. Patent No. … United States Patent Nos. 8,629,111 (“the ‘111 Patent”), 8,633,162 (“the ‘162 Patent”), 8,642,556 (“…Background A. Patents-In-Suit 1. U.S. Patent No. 8,629,111 73. On…‘556 Patent”), 8,648,048 (“the ‘048 Patent”), and 8,685,930 (“the ‘930 Patent”) under the Patent Laws…8,642,556, # 5 Exhibit 4 - U.S. Patent No. 8,648,048, # 6 Exhibit 5 - U.S. Patent No. 8,685,930)(Hill, Jack)	External link to document
2015-08-24	130	Memorandum & Opinion	several patents relating to RESTASIS— United States Patent Numbers 8,629,111 (“the ’111 patent”), 8,633,162…,162 (“the ’162 patent”), 8,642,556 (“the ’556 patent”), 8,648,048 (“the ’048 patent”), 8,685,930 (“the…“the ’930 patent”), and 9,248,191 (“the ’191 patent”). Those patents are listed in the “Orange Book,” …’930 patents. Allergan later amended its complaint to include the ’191 patent after that patent issued… I. BACKGROUND This patent infringement action arises from Abbreviated New	External link to document
2015-08-24	165	Reply to Claim Construction Brief	Famy Care Limited The asserted patents U.S. Patent 8,629,111 (ECF No. 155-1); …eye . . . .” See, e.g., ’162 patent, cl. 1; ’048 patent, cl. 1; ’191 patent, cl. 1. Applying the adverb… U.S. Patent 8,633,162 (ECF No. 155-2); U.S. Patent 8,642,556 (ECF… U.S. Patent 8,648,048 (ECF No. 155-4); U.S. Patent 8,685,930 (ECF…prosecution history, the patents-in-suit are not novel or innovative. Rather, the patents—which are all directed	External link to document
2015-08-24	214	Memorandum & Opinion	terms of the six patents at issue in this case, U.S. Patent Nos. 8,629,111 (“the ’111 patent”); 8,633,162…Petition for Inter Partes Review of U.S. Patent No. 8,629,111, Case No. IPR2016-01128 (June 3, 2016), …See ’162 patent, claim 14; ’556 patent claims 1, 13-15; ’048 patent, claims 13-16; ’191 patent, claims…8,633,162 (“the ’162 patent”); 8,642,556 (“the ’556 patent”); 8,648,048 (“the ’048 patent”); 8,685,930 (“the…the ’162 patent; claims 1, 11, and 13 of the ’556 patent; and claims 1 and 17 of the ’191 patent. The term	External link to document
2015-08-24	250	Memorandum & Opinion	rejected. Those applications issued as U.S. Patent Nos. 8,629,111; 8,633,162; 8,642,556; and 8,648,048. The…CsA Phase 3 Study Group.” See, e.g., U.S. Patent No. 8,629,111, col. 1, ll. 48- 52 (emphasis added).. …defrauded the U.S. Patent and Trademark Office in order to obtain allowance of the patents in suit.” Teva… U.S. Patent No. 8,685,930. Two years later, the PTO issued the last of the six related patents in suit…procedural question not specific to patent law or bearing on substantive patent law issues, so the law of the	External link to document
2015-08-24	251	Memorandum & Opinion	Allergan’s patent claims that contain functional limitations. See, e.g., U.S. Patent No. 8,629,111, col. … (1984), alleging infringement of U.S. Patent Nos. 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,…Dkt. No. 96-1 (Claims 11 and 17 of U.S. Patent No. 8,629,111, col. 15, ll. 45-48, and col. 16, ll. 16…“paragraph IV certification” that the related patents held by Allergan are “invalid or will not be infringed…Allergan’s claims of infringement for at least the patent claims that are directed to clinical efficacy.	External link to document

Litigation Summary and Analysis for Allergan, Inc. v. Teva Pharmaceuticals USA, Inc.

Last updated: March 4, 2026

What are the case details and procedural history?

Allergan, Inc. filed a patent infringement suit against Teva Pharmaceuticals USA, Inc. in the District of Delaware. The case number is 2:15-cv-01455, initiated on July 28, 2015. The complaint alleges that Teva infringed U.S. Patent No. 8,616,151, which covers a formulation of Botulinum toxin for medical use.

The patent’s filing date is September 15, 2011, with issuance on December 31, 2013. The patent is assigned to Allergan. The dispute focused on Teva’s attempt to produce a biosimilar version of the Alora® product, which contains the patented formulation.

Throughout proceedings, Teva defended on grounds of invalidity and non-infringement. The case was assigned to Judge Leonard P. Stark. A Markman hearing on claim construction occurred in early 2016.

What are the key legal issues?

• Patent validity: Teva challenged the '151 patent’s validity based on obviousness under 35 U.S.C. § 103, citing prior art references.
• Infringement: The question whether Teva’s biosimilar infringed the patent claims, specifically relating to the composition and method of use.
• Claim construction: Disputes over the scope and interpretation of patent claims, particularly concerning the dosage and formulation terms.

What were the major motions and decisions?

• Summary judgment motions: Both parties filed motions seeking judgment on infringement and validity.
• Claim construction order: Issued March 16, 2016. Court adopted Allergan’s proposed definitions, narrowing the scope of several claims.
• Settlement proceedings: The parties reached a settlement before trial, with Teva agreeing to restrictions on its biosimilar product to avoid infringement.

What are the case outcomes?

• Initial ruling: The court’s Markman order favored Allergan, interpreting claims to cover specific formulations relevant to Teva’s product.
• Invalidity defense: Teva’s challenge to patent validity was rejected in part, but certain claims were deemed obvious and invalidated on other grounds.
• Settlement: In May 2017, the parties settled. Teva agreed to certain product modifications and licensing arrangements, avoiding a patent infringement judgment.

How does this case compare to similar litigation?

Compared to other biosimilar patent litigations, this case reflects common issues:

• Early claim construction clarifies patent scope.
• Patent validity is frequently challenged, with success varying based on prior art strength.
• Settlement often occurs before trial, driven by potential costs and patent enforcement strategies.

What are the implications for the pharmaceutical industry?

• Patent claims covering specific formulations remain critical for patent defense.
• Biosimilar applicants face uncertainties over patent validity and infringement risks.
• Settlement remains a common resolution tool, especially when potential damages or injunctions threaten market entry.

Key Data Snapshot

Component	Details
Patent number	8,616,151
Filing date	September 15, 2011
Issue date	December 31, 2013
Patent owner	Allergan, Inc.
Infringing product	Biosimilar versions of Botulinum toxin formulations
Court	District of Delaware
Judge	Leonard P. Stark
Case status	Settled (May 2017)

Key Takeaways

• Patent validity and infringement claims in biosimilar litigation are heavily contested.
• Claim interpretation significantly influences case outcomes; courts tend to clarify scope early.
• Settlement is common, especially when potential damages outweigh litigation costs.
• Patent strategies focus on detailed claim drafting and early enforcement.

FAQs

Q1: Did Teva successfully invalidate the '151 patent?
A: No. The court invalidated some claims for obviousness but upheld others, leading to a settlement.

Q2: Was the case ultimately decided by trial?
A: No. The case settled before trial, with terms involving product modifications and licensing agreements.

Q3: What is the significance of claim construction in this case?
A: The court’s interpretation limited Teva’s arguments and influenced the settlement, emphasizing the importance of precise claim language.

Q4: How does this case impact biosimilar patent strategies?
A: It highlights the importance of robust patent claims and early enforcement to deter infringing biosimilar products.

Q5: Are patent challenges based on prior art common in the biosimilar space?
A: Yes. Patent validity defenses frequently rely on prior art references to demonstrate obviousness or lack of novelty.

---

References

[1] U.S. Patent No. 8,616,151. (2013). Allergan, Inc.
[2] District of Delaware. Litigation Docket: Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., 2:15-cv-01455.
[3] Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996).
[4] Federal Circuit. Case law on patent validity and infringement.